作者
Evangelos Terpos, Ioannis P Trougakos, Maria Gavriatopoulou, Ioannis Papassotiriou, Aimilia D Sklirou, Ioannis Ntanasis-Stathopoulos, Eleni-Dimitra Papanagnou, Despina Fotiou, Efstathios Kastritis, Meletios A Dimopoulos
发表日期
2021/7/1
期刊
Blood, The Journal of the American Society of Hematology
卷号
137
期号
26
页码范围
3674-3676
出版商
American Society of Hematology
简介
Patients with multiple myeloma (MM) are at an increased risk for infection because of their immunocompromised state, old age, and comorbidities. 1 Coronavirus disease 2019 (COVID-19) causes moderate to severe acute respiratory dysfunction in 77% of patients with MM, and~ 8% end up in critical condition. 2 More than 80% of patients with MM who are infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) require hospitalization, 3 whereas~ 33% of hospitalized MM patients with COVID-19 may die because of the infection. 4 This is mainly due to the limited therapeutic options for COVID-19. 5
Vaccination against SARS-CoV-2 could be an important preventive strategy against COVID-19 for patients with MM, but its efficacy in MMis largely unknown. 6 The BNT162b2 messenger RNA (mRNA) vaccine is the first anti–SARS-CoV-2 vaccine approved by the US Food and Drug Administration and …
引用总数
2020202120222023202415470194